Older and younger chronic leukemia patients may need different therapy
2012-12-12
(Press-News.org) People who develop chronic lymphocytic leukemia (CLL) are typically age 65 and older, but participants in CLL clinical trials are usually several years younger;
The age of CLL patients is not usually considered when determining treatment;
This study suggests that older and younger CLL patients require different therapy.
COLUMBUS, Ohio – Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
Age is usually not considered when determining treatment for people with CLL, but this study indicates that older people with CLL may not respond as well to the therapy used for most patients.
The study was published Dec. 10 in the Journal of Clinical Oncology.
"Our analysis shows that optimal therapy for younger and older patients with chronic lymphocytic leukemia is likely to be different, at least when using current treatments," says first author Dr. Jennifer Woyach, assistant professor of hematology at the OSUCCC – James.
"We hope this study will shape future research by highlighting the importance of enrolling older patients on clinical trials and of developing trials that specifically target older patients."
Doctors diagnose about 15,000 new cases of chronic lymphocytic leukemia (CLL) annually in the United States, making it the most common form of leukemia. It remains incurable, and about 4,400 Americans die of the malignancy each year. CLL most often occurs in people older than age 65; the average age at diagnosis is 72. Yet, most CLL clinical-trial participants are in their early 60s.
"Our findings apply to both routine care of CLL patients 70 years and older and to future CLL trials," says principal investigator Dr. John Byrd, a CLL specialist and professor of medicine, of medicinal chemistry and of veterinary biosciences at the OSUCCC – James.
"The study suggests that chlorambucil is superior to fludarabine in older patients, and that CD20 antibody therapies such as rituximab are beneficial as front-line therapy for all CLL patients, regardless of age," says Byrd, who is the D. Warren Brown Designated Chair in Leukemia Research.
"These data also show that future treatment trials for older adults with CLL should build on CD20 antibody therapies such as rituximab and ofatumumab, but not on fludarabine or alemtuzumab."
Byrd, Woyach and their colleagues reviewed 663 CLL patients who were enrolled in four sequential CLL clinical trials evaluating front-line therapies. The researchers looked for differences in treatment outcomes between older and younger patients to identify the most effective therapy for older adults.
The four trials, all sponsored by the Cancer and Leukemia Group B (CALGB) clinical cooperative group, compared these treatments: chlorambucil versus fludarabine, fludarabine plus rituximab versus fludarabine, fludarabine with consolidation alemtuzumab, and fludarabine plus rituximab with consolidation alemtuzumab.
Key conclusions include:
Fludarabine versus chlorambucil: Fludarabine improved progression-free survival and overall survival among patients younger than age 70 but chlorambucil tended to produce higher overall survival in patients older than 70.
Rituximab combined with fludarabine, versus fludarabine alone, improves progression-free and overall survival in both younger and older patients.
Alemtuzumab consolidation therapy after chemotherapy or chemoimmunotherapy does not improve progression-free or overall survival in either younger or older patients.
###
Funding from the NIH/National Cancer Institute (grants CA31946, CA33601 and CA140158), the Leukemia and Lymphoma Society, the Harry Mangurian Foundation and the D. Warren Brown Family Foundation supported this research.
Other researchers involved in this study were Amy S. Ruppert and Susan Geyer of Ohio State; Kanti Rai and Jonathan Kolitz of North Shore-Long Island Jewish Medical System; Martin S. Tallman, Memorial Sloan-Kettering Cancer Center; Thomas S. Lin, GlaxoSmithKline; Frederick R. Appelbaum, Fred Hutchinson Cancer Research Center; Andrew R. Belch, Cross Cancer Institute, Edmonton, Alberta, Canada; Vicki A. Morrison, University of Minnesota and Veterans Affairs Medical Center; and Richard A. Larson, University of Chicago.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 210-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by
U.S.News & World Report.
ELSE PRESS RELEASES FROM THIS DATE:
Researchers shed light on the workings of the body's immune response
2012-12-12
Researchers from Queen Mary, University of London have discovered that two proteins which are believed to play a key role in controlling the body's immune response are found in lower levels in T lymphocytes from patients with multiple sclerosis (MS).
The study found that MS patients' T lymphocytes – types of white blood cells which play an important role in the immune system – were defective at producing the proteins and that this was associated with increased levels of molecules which promote inflammation. The findings are reported in the Journal of Immunology¹.
The ...
Can algae-derived oils support large-scale, low-cost biofuels production?
2012-12-12
New Rochelle, NY, December 12, 2012—ExxonMobil and many other energy companies are investing hundreds of millions of dollars to develop transportation biofuels from renewable resources such as the oil or hydrocarbons produced by microalgae. As global supplies of fossil fuels continue to shrink, biofuels derived from algae represent one promising source of low-cost, scalable renewable energy. The feasibility and economic projections for large-scale biofuels production from microalgae are examined in a Review article and accompanying Commentary published in Disruptive Science ...
Novel test identifies patients most likely to benefit from ALK inhibition therapy
2012-12-12
Philadelphia, PA, December 12, 2012 – Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients are highly responsive to ALK-specific kinase inhibitors such as crizotinib. However, current diagnostic tests have limitations. Researchers have now developed and tested a promising new method for screening ALK fusions in NSCLC. This new diagnostic assay offers a cost-effective and easy-to-perform alternative ...
Frog-in-bucket-of-milk folklore leads to potential new antibiotics
2012-12-12
Following up on an ancient Russian way of keeping milk from going sour — by putting a frog in the bucket of milk — scientists have identified a wealth of new antibiotic substances in the skin of the Russian Brown frog. The study appears in ACS' Journal of Proteome Research.
A. T. Lebedev and colleagues explain that amphibians secrete antimicrobial substances called peptides through their skin. These compounds make up the majority of their skin secretions and act as a first line of defense against bacteria and other microorganisms that thrive in the wet places frogs, toads, ...
A promising clinical trial to reduce the severity of autistic disorders
2012-12-12
This press release is available in French.
Although this therapy is not curative, it nevertheless reduced the autistic disorders' severity in three-quarters of the children. The researchers have filed a request for authorisation to perform a multi-centre European clinical trial in order to determine more precisely the population concerned by this therapy.
Details of this work have been published in the Translational Psychiatry review dated 11 December 2012.
Contribution made by the fundamental research on neuronal chloride
Previous work carried out by the team of ...
New twist on using biomass for perfume, cosmetic, personal care products
2012-12-12
In a new approach for tapping biomass as a sustainable raw material, scientists are reporting use of a Nobel-Prize-winning technology to transform plant "essential oils" — substances with the characteristic fragrance of the plant — into high-value ingredients for sunscreens, perfumes and other personal care products. The report on the approach, which could open up new economic opportunities for tropical countries that grow such plants, appears in the Journal of the American Chemical Society.
Deryn Fogg, Eduardo dos Santos and colleagues explain that breaking down plant ...
New geometries: Researchers create new shapes of artificial microcompartments
2012-12-12
In nature, biological functions are often carried out in tiny protective shells known as microcompartments, structures that provide home to enzymes that convert carbon dioxide into energy in plant cells and to viruses that replicate once they enter the cell.
Most of these shells buckle into an icosahedron shape, forming 20 sides that allow for high interface with their surroundings. But some shells — such as those found in the single-celled Archaea or simple, salt-loving organisms called halophiles —break into triangles, squares, or non-symmetrical geometries. While these ...
Scientists train honey bees to stick out their tongues
2012-12-12
Honey bees are a highly organized, social species, as demonstrated by their complex colonies and the geometric structure of their hives. For hive building, the honey bee strongly relies on its tactile sense, and a new video-article in JoVE (Journal of Visualized Experiments) illustrates a novel tactile conditioning experiment using honey bees. The technique, presented by the lab of Dr. Volker Dürr of Bielefeld University, trains honey bees to stick out their tongues when their antennae touch an object. This procedure allows researchers to analyze how changes in antennal ...
A second ascent of chemistry's Mt. Everest
2012-12-12
In science's equivalent of ascending Mt. Everest, researchers are reporting success in one of the most difficult challenges in synthetic chemistry — a field in which scientists reproduce natural and other substances from jars of chemicals in a lab. The feat, reported in the Journal of the American Chemical Society, involved synthesis of a rare substance with promising in vitro anti-cancer effects found naturally in tiny amounts in a Chinese medicinal herb.
Samuel J. Danishefsky and Feng Peng explain that maoecrystal V occurs naturally in a plant growing in China's Yunnan ...
Will climate change cause water conflict?
2012-12-12
International researchers from 14 institutions met in Nicosia (Cyprus) on the 10th and 11th of December to present and debate the results of studies on water, conflict and security conducted in the past three years in a variety of locations in the Mediterranean, Middle East and Sahel under the CLICO research project. The CLICO project explored the social dimensions of climate change and in particular, conflicts related to water, and the threats this may pose for national and human security. The project was led by the Institute for Environmental Science and Technology (ICTA) ...